Neoadjuvant DurvalumabOlaparib Active in MuscleInvasive Bladder Cancer

Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

12:45 EST 15 Feb 2020 | OncLive

A neoadjuvant regimen of durvalumab plus olaparib induced a pathologic complete response rate of 50% in patients with muscle-invasive bladder carcinoma.

Original Article: Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

More From BioPortfolio on "Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer"